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Abstract
Background: People with dementia (PWD) experience ten times as many incident falls as people without
dementia. Little is known about how best to deliver services to people with dementia following a fall. We used an
integrated, mixed-methods approach to develop a new intervention which combines theory generated via a realist
synthesis and data on current provision and pathways, gathered through a prospective observational study as well
as qualitative interviews, focus groups and ethnographic observation. This intervention is to be tested in a feasibility
study in the UK National Health Service.
Methods: People living with dementia in one of three geographical areas will be eligible for the study if they
experience a fall requiring healthcare attention and have an informal carer. Potential participants will be identified
by community services (primary care, paramedics, telecare), secondary care (ED, facilitated discharge services,
rehabilitation outreach teams) and research case registers. Participants will receive a complex multidisciplinary
intervention focused on their goals and interests for up to 12 weeks. The intervention will be delivered by
occupational therapists, physiotherapists and rehabilitation support workers. Feasibility outcomes will include
recruitment and retention, suitability and acceptability of outcome measures and acceptability, feasibility and
fidelity of intervention components. PWD outcome measures will include number of falls, Montreal Cognitive
Assessment (MOCA), European Quality of Life Instrument (EQ-5D-5L), Quality of Life–Alzheimer’s Disease Scale (QOL-
AD), Modified Falls Efficacy Scale (MFES) and Goal Attainment Scaling (GAS). PWD outcome measures completed by
an informal carer will include Disability Assessment for Dementia (DAD), EQ-5D-5L Proxy, QoL-AD Proxy and a
Health Utilisation Questionnaire (HUQ). The carer outcome measure will be the Zarit Burden Interview (ZBI). An
embedded process evaluation will explore barriers and facilitators to recruitment and intervention delivery.
Discussion: The study results will inform whether and how a larger multicentre RCT should be undertaken. A full
RCT would have the potential to show how outcomes can be improved for people with dementia who have fallen.
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Background
Recent estimates suggest that there are 850,000 people
living with dementia (PWD) in the UK, which will in-
crease to over 1 million by 2025 and 2 million by 2051 if
current trends remain stable [1]. While the number of
people with dementia in care settings has increased,
most individuals with dementia still live in the commu-
nity [2]. The annual prevalence of falls in PWD ranges
from 47 to 90%, depending on dementia subtype, with
PWD living in their own home sustaining almost ten
times more falls per year than cognitively intact older
people. [3]. Their falls are more likely to be injurious
than those of controls. Where injuries are sustained,
PWD are less likely to recover well than other older
people [4]. Falls and fall-related injuries are therefore a
significant cause of morbidity and mortality in PWD.
There is presently limited evidence to guide the man-
agement of falls and fall-related injuries in people with
dementia, and available evidence tends to be focused on
those who sustain more serious injuries, such as frac-
tures [5–10]. While multifactorial falls services can pre-
vent further falls in cognitively intact older people [11,
12], their effectiveness for people with dementia has not
been demonstrated [13]. Yet, there are potentially sub-
stantial benefits to be gained if the outcome of these falls
and injuries in PWD could be improved. For example, a
successful intervention has the potential to reduce psy-
chological morbidity and improve wellbeing [14]. There
is also evidence to suggest that rehabilitation interven-
tions can improve physical functioning in people with
cognitive impairment following hospital admission [15,
16] and that exercise may reduce the risk of future falls
in this patient group [17].
The overall aim of this study is to assess whether it is
possible to design a complex intervention to reduce falls
in PWD living in their own homes who have sustained a
fall requiring healthcare attention. The intervention was
developed in earlier phases of the study (using an inte-
grated, mixed-methods approach to develop a new inter-
vention which combines theory generated via a realist
synthesis and data on current provision and pathways,
gathered through a prospective observational study as well
as qualitative interviews, focus groups and ethnographic
observation). We are now conducting a study to assess
the feasibility and acceptability of the intervention and se-
lected study procedures, and identify any changes needed
prior to a full-scale randomised controlled trial (RCT).
Objectives
Primary objective
The primary aim of this study is to determine whether
to progress to a full-scale randomised controlled trial
which aims to reduce falls in PWD who have sustained a
fall requiring healthcare attention.
Secondary objectives
The secondary aims of this study are to determine the re-
cruitment and retention rates from a range of settings, to
identify issues related to the suitability and acceptability of
outcome measures, and to assess the factors influencing
the acceptability and implementation of the intervention.
Methods
This is a single arm feasibility study of the study inter-
vention. We have followed the Standard Protocol Items:
Recommendation for Interventional Trials (SPIRIT)
guidance [18] and the SPIRIT checklist is provided in
Additional file 1. In developing the intervention and de-
signing the feasibility study, we have followed the Med-
ical Research Council (MRC) guidance on developing
and evaluating complex interventions [19]. We provide a
description of the intervention using the Template for
Intervention Description and Replication (TiDieR)
guidelines [20] in Additional file 2. In accordance with
the MRC guidance on process evaluation of complex in-
terventions [21], we have developed a logic model (to be
reported elsewhere). The study will be carried out in
three research sites, reflecting a range of National Health
Service (NHS) practice to allow for generalisability.
Recruitment, screening and consent
We plan to recruit a minimum of 30 people with dementia
(PWD) and 30 informal carers for the intervention and up
to 28 professionals for the process evaluation (beginning
5th February, ending 29th April 2018). Participants will be
recruited from three geographical areas in the UK (Newcas-
tle upon Tyne, Norwich and Stockton upon Tees).
Inclusion criteria for people with dementia
 A known diagnosis of dementia (any subtype), made
prior to entry into the study, by a specialist in
dementia care (Geriatrician, Neurologist or Old Age
Psychiatrist).
 Must have sustained at least one fall requiring
healthcare attention (via 111 (a free-to-call single
non-emergency number medical helpline operating
in England and Scotland), district/practice nurse or
minor injuries unit as well as the services outlined
below), within 1 month prior to their identification
as a potential study participant. A fall will be defined
as an event whereby a person comes to lie on the
ground or another lower level with or without loss
of consciousness. The fall leading to their identifica-
tion will be known as the index fall.
 Must be dwelling in the community at the time of
the index fall and returning to the community at the
time of the intervention.
Allan et al. Pilot and Feasibility Studies           (2018) 4:170 Page 2 of 13
 Must have an informal carer available to assist with
completion of the diaries.
 Either has capacity to consent to participation, or a
personal or nominated consultee who is able to give
an opinion on the participation of the PWD.
Exclusion criteria for people with dementia
 Diagnosis of dementia cannot be confirmed by the
primary care team within 2 weeks of their being
identified as a potential participant.
 Participant found to be dwelling in residential or
nursing care, or to have been a hospital inpatient at
the time of the index fall.
 Participant refuses consent, or lacks capacity and
does not have personal or nominated consultee, or
their personal or nominated consultee declines
participation.
 Not able to communicate in English either because
they are not a native English speaker or due to
advanced dementia.
 Informal carer declines participation in the study.
Identification and recruitment of people with dementia
We will compare the ease of identification of PWD via
three main routes (community settings; secondary care
settings; research registers); this will inform potential re-
cruitment strategies for a future definitive trial of the de-
veloping an intervention for fall related injuries in
dementia (DIFRID) intervention.
Community services used for recruitment are primary
care, paramedic services and telecare services. Secondary
care services used to identify potential study participants
are emergency departments (ED), supported discharge
teams and rehabilitation outreach teams. We will also
recruit potential participants from the North East (NE)
and North Cumbria (NC) Clinical Research Network
(CRN) Case Register and Join Dementia Research (JDR).
At each stage of the recruitment procedure, a list of all
potential participants who had contact with the research
study will be maintained at each site. If the person has
declined or not responded to an invitation from the re-
search team or not been recruited for another reason
then they will not receive any further contacts from the
research team.
Confirmation of PWD eligibility
With the exception of potential participants identified
through primary care (who will have been identified via
the Quality and Outcomes Framework (QOF) dementia
register), we will have to confirm that the participant has a
diagnosis of dementia prior to formal recruitment to the
study. At first identification in the relevant setting, partici-
pants will be given or posted a summary participant
information sheet (PIS). In community settings, partici-
pants will be asked to send in an opt in form giving their
contact details. In secondary care settings, it will be pos-
sible to access contact details via patient notes. After they
have received the summary, all potential participants will
be contacted by the clinical trials associate (CTA) by tele-
phone. During the initial telephone call from the CTA to
discuss participation, the CTA will seek verbal consent to
contact the general practitioner (GP) practice to check
whether the person is on the dementia QOF register. If
secondary care records indicate that the person should be
on the QOF register the GP will be invited to update the
QOF register to include this person.
If the participant is on the dementia QOF register, the
CTA will send a full PIS. A clinical researcher will con-
tact them again to confirm eligibility and, if still inter-
ested, to arrange a home visit to take consent and
undertake a baseline assessment if appropriate. Partici-
pants who are not on the dementia QOF register will be
sent a letter explaining that they are not eligible but
thanking them for their interest in the study.
Consent
Participants will be required to give informed consent to par-
ticipation in the intervention study in accordance with the
Declaration of Helsinki. Due to the nature of dementia, some
participants may lack the capacity to give full informed con-
sent. In this case, the provisions of the Mental Capacity Act
(2005) will apply. PWD will be asked to give consent appro-
priate to their level of understanding, ranging from written
informed consent to account being taken of verbal and
non-verbal communication in determining willingness to
participate. In those individuals found to be without capacity
to give full informed consent, the CTA will identify a per-
sonal or nominated consultee and seek their advice regarding
participation by letter and/or phone call. If a consultee thinks
that the person would not have wanted to participate in the
study, the participant will not be recruited and they will not
be contacted any further about the study. If they do not give
an opinion, it will be assumed that consent is withheld and
they will not be recruited or contacted further about the
study. Any PWD appearing distressed by participation or
withdrawing consent will be excluded from the study with-
out prejudice to clinical care.
Identification and recruitment of informal carers
We anticipate that many PWD seeking healthcare atten-
tion will be accompanied by an informal carer. In this situ-
ation, the informal carer will be aware of the study from
the outset. They will be issued with an informal carer PIS
by the CTA at the earliest opportunity. If PWD are not ac-
companied by an informal carer, we will ask them to iden-
tify if they have an informal carer who might be interested
in being involved in the study with them.
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Recruitment to the process evaluation
The initial consent process with PWD and informal
carers will include consent for optional participation in
the qualitative aspects of the study. We will purposively
select a sample of consenting PWD and informal carers
for observation and interview. Examples of participant
characteristics which will be considered when sampling
will include gender, falls history, goals and activities
identified for the intervention, intensity of the interven-
tion and adherence to the intervention (through partici-
pant diaries and discussions with the therapists
delivering the intervention). We will aim to observe the
delivery of all components of the intervention in all sites
assuming this is logistically possible. This will enable us
to explore whether and how the sessions are tailored to
individuals, activities are embedded into usual routines
and the role of the informal carer in the intervention.
Consent will be sought from all professionals with the
exception of those involved in developing, training and
supervising the intervention and those directly involved in
delivering the intervention. Participation in observation
and/or interviews and informal discussions will be part of
their role and therefore not optional. A PIS will be pro-
vided to make these expectations clear and to outline the
rationale for these qualitative aspects of the study.
To ascertain the ‘fit’ of the intervention with existing
services, and the impact on referral patterns, we will li-
aise with the multidisciplinary team (MDT) and staff de-
livering the intervention to identify where referrals have
been made. As part of their initial assessment, the
physiotherapist and occupational therapist will explore
current support services being used by the PWD. We
will use information from the assessment to identify a
purposive sample of staff whom we would like to inter-
view. Selected professionals will be sent an invitation let-
ter and PIS. This will be followed up by a telephone call
within a week to check whether the professional is will-
ing to take part and, if so, to arrange a meeting to take
consent and conduct the interview.
CTAs responsible for recruitment and professionals
involved in making the initial approach will be sent a
PIS by the qualitative team towards the end of the re-
cruitment period. This will be followed up by email or
telephone to discuss participation and, if appropriate, ar-
range the interview.
Data collection and follow up
Baseline assessments and data
Baseline data for the outcome measures described below
will be recorded by a clinical researcher for PWD and
informal carers consenting to the intervention study
within 2 weeks of confirmation of eligibility (Table 1).
After the baseline assessment, the clinical researcher will
send a referral to the intervention team using a structured
referral form with details of the baseline assessments of the
PWD and informal carer. The intervention team will then
arrange an initial intervention assessment within 2 weeks.
Follow up assessments
At 12 weeks, the clinical researcher will carry out a second
visit to repeat most of the outcome measures completed
at the baseline assessment with PWD and informal carers
(see Table 1). The exception is the Montreal Cognitive As-
sessment (MOCA); completing this at baseline will enable
us to describe the cognitive function of participating
PWD, but it will not be repeated as the intervention is not
expected to have an impact on cognition. The Health Util-
isation Questionnaire (HUQ) will be completed by the
clinical researcher with the informal carer on behalf of the
PWD to determine the use and health and social care ser-
vices by the PWD in the preceding 12 weeks.
Outcome measures
PWD outcome measures
All outcome measures will be completed by those PWD
with the capacity to do so. With the exception of the
MOCA, all measures will be completed at baseline and
12 week follow-up (see Table 1). The schedule of events
is shown in Table 2.
Number of falls
This will be assessed through prospective completion of
a diary throughout the 12-week intervention with the
aid of an informal carer when required. Participants will
be asked to record whether they had any falls on each
day and, if so, to describe the context and consequences
of the fall. These data will be used to calculate the pro-
portion of participants with one or more falls and the
fall rate per person year.
Montreal Cognitive Assessment
This measure will be completed at baseline only to allow us
to describe the cognitive profile of participating PWD [22].
Modified Falls Efficacy Scale
The psychological consequences of falling will be deter-
mined using the Modified Falls Efficacy Scale (MFES)
[23]. This is a 14-item measure of falls efficacy (or fear
of falling), based on the original Falls Efficacy Scale [24].
Goal Attainment Scaling
As part of the intervention, therapists will set individua-
lised goals with participants. The goals will be agreed
with the PWD by the therapists at the first therapy ses-
sion and assigned ‘weights’. Goal Attainment Scaling
(GAS) is a method of scoring the extent to which these
goals are achieved in a way that is standardised for ana-
lysis [25, 26]. Progress towards goals will be measured at
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the final intervention visit, allowing a numerical score to
be calculated at 12 weeks.
Generic Quality Of Life Instrument
The EuroQol-5 Dimension-5 Levels (EQ-5D-5L) is a
standardised instrument used to measure generic
health-related quality of life [27]. The five dimensions
are mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. The five levels range from no
problems to extreme problems.
Quality of Life–Alzheimer’s Disease Scale
The Quality of Life–Alzheimer’s Disease Scale (QOL-AD)
is a standardised instrument for measuring quality of life
for PWD [28, 29]. It is a 13-item scale administered via an
interview. It includes the domains of physical condition,
mood, memory, functional abilities, interpersonal relation-
ships, ability to participate in meaningful activities, financial
situation and global assessments of self as a whole and
QOL as a whole.
PWD outcome measures completed by an informal carer
With the exception of the Health Utilisation Question-
naire, all outcome measures will be completed by an in-
formal carer at both baseline and 12-week follow up.
Disability Assessment For Dementia
The Disability Assessment for Dementia (DAD) is a stan-
dardised instrument measuring the functional ability of
PWD in activities of daily living (ADLs) [30]. It is 40-item
scale administered via an interview with a proxy.
EQ-5D-5L proxy
The proxy version of the EQ-5D-5L will be completed
by informal carers regardless of whether or not the
PWD lacks capacity.
Table 1 Assessment of outcome measures
Completed by Time to complete Baseline visit 12-week follow-up visit
MOCA Patient 10 min ✓
EQ-5D-5L Patient 5 min ✓ ✓
QOL-AD Patient 5–10 min ✓ ✓
MFES Patient 5–15 min ✓ ✓
GAS Patient 20–40 min ✓a ✓a
TUAG Patient 5 min ✓a ✓a
DAD Informal carer (proxy) 15 min ✓ ✓
EQ-5D-5L Informal carer (proxy) 5 min ✓ ✓
QOL-AD Informal carer (proxy) 5–10 min ✓ ✓
HUQ Informal carer (proxy) 20 min ✓
ZBI Informal carer 10 min ✓ ✓
aThis measure will be completed with the therapist after the initial assessment and repeated at the final intervention visit
Table 2 Schedule of events
Baseline assessment
(clinical researcher)
Week 1
(intervention)
Weeks 2–12
(intervention)
Week 12 follow-up assessment
(clinical researcher)
Informed consent (including consent for observation
and/or interview)
X
Baseline data collected (see Table 1) x
2 Assessment visits by intervention team including
timed up and go test
X
Up to 22 visits by Intervention team. Final visits will
include goal attainment scaling and timed up and go test
X
Completion of diary X
Informed consent of professionals and participants
and observation of interventions received
X X
Informed consent and qualitative interview with
some professionals regarding views on intervention.
X
Qualitative interview with patients, informal carers
and professionals views on intervention
X
Follow up outcome data collected (see Table 1) X
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QoL-AD proxy
The proxy version of the QoL-AD will be completed by
informal carers regardless of whether or not the PWD
lacks capacity.
Health Utilisation Questionnaire
This questionnaire will be completed by the clinical
researchers using information from informal carers at
12 weeks to ascertain which additional health and so-
cial care services have been used by the PWD during
the 12-week period of the intervention. We will use
informal carers as proxy respondents since it is un-
likely that many PWD will be able to provide detailed
information about retrospective service use. To facili-
tate recall, we have included a section for health and
social care appointments in the prospective diary.
This will be a pilot of the questionnaire for a future
definitive trial.
Informal carer outcome measure
Zarit Burden Interview
Carer burden will be measured using Zarit Burden Inter-
view (ZBI), a series of 22 questions designed to elicit the
impact of the patient’s disabilities on the life of the care-
giver [31]. This will be completed with informal carers
at baseline and follow-up.
DIFRID intervention
Description of the DIFRID intervention
An overview of the intervention is provided in Fig. 1. De-
tails of the intervention are supplied in Additional file 3.
The intervention will be a multidisciplinary intervention
primarily delivered in the participant’s home. The inter-
vention will be tailored to the abilities of the participant,
their likes and dislikes for activities and goals agreed be-
tween the therapist and the participant and their informal
carer. The number of sessions will be tailored to the needs
of the participant; the first two sessions will be assessment
Fig. 1 Overview of the DIFRID intervention
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sessions followed by up to 22 therapy sessions delivered
over a total period of up to 12 weeks. The assessment and
therapy procedures are described in a bespoke manual for
professionals (Additional file 4).
Feasibility outcome measures
Feasibility of recruitment and retention
We will explore the feasibility of different approaches to
PWD identification and recruitment. We will also con-
sider the rates of conversion to study participation and
retention. Specifically, we will report on:
 The number of PWD identified through community
and secondary care, and case registers/JDR
 The proportion of PWD who give permission for us
to check their medical records to determine
eligibility
 The proportion of PWD who meet the eligibility
criteria
 The proportion of eligible PWD who agree to
participate in the study
 The proportion of eligible informal carers who agree
to participate in the study
 The proportion of participating PWD and informal
carers who start the intervention
 The proportion of participating PWD and informal
carers who remain in the study until study completion
 The proportion of participating PWD and informal
carers completing each outcome measure at baseline
and 12-week follow-up
CTAs responsible for recruitment and professionals
responsible for the initial approach to potential partici-
pants will be invited to take part in a formal interview to
explore the feasibility and acceptability of the different
approaches to patient identification.
Assessment of suitability and acceptability of outcome
measures
We will also examine the response rates, acceptability
and feasibility of outcome measures described in Table 1
that could be used in a definitive trial. We will include a
small number of open questions at the final follow-up
interview to explore their views on the measures used
and to identify any additional outcomes of the interven-
tion that have not been captured. The clinical re-
searchers responsible for collecting outcome data will
also be invited to take part in a brief qualitative inter-
view to give their feedback on the outcome measures.
Assessment of the feasibility and acceptability of
intervention delivery
Since the intervention is multi-dimensional and tailored
to the individual, we will use mixed methods and seek
the views of a range of stakeholders. Quantitative ana-
lysis will consider:
 The proportion of staff attending all training and
supervision sessions and MDT meetings
 The number, frequency and duration of training and
supervision sessions, and MDT meetings
 Time spent with the patient and time spent
travelling to appointments
 The proportion of patients discussed at MDT
meetings and actions taken
 The proportion of patients seen by a geriatrician
 The proportion of patients reviewed by the MDT at
six and twelve weeks and actions taken
 How the assessment documentation was used in
practice, for example, whether all sections were
completed
 The nature of goals set and alignment of activities
with these goals
 Referrals made to other services
 Adherence with agreed activities by PWD
Additional qualitative work will provide a more nuanced
understanding of these data and allow us to explore
whether and how the intervention will need to be adapted
prior to a full trial. We will either directly observe or use
audio recordings of intervention training, delivery and
supervision in all sites; this will enable us to explore ad-
herence and variation between and within sites. Observa-
tion will be supplemented with semi-structured interviews
with a range of stakeholders to explore:
 The ‘fit’ of the intervention with staff usual working
practices
 The acceptability of the intervention and suggested
changes or improvements to the content, delivery or
timing of the intervention
 Assessment of training and intervention delivery
 The feasibility and perceived value of MDT
meetings
 The feasibility of different components of the
intervention (e.g. goal setting and tailoring)
To ensure that we capture the views of different stake-
holders, we will interview staff delivering training and
supervision, staff delivering the intervention, members
of the MDT, PWD and informal carers receiving the
intervention and health and social care staff who are
concurrently providing care to the PWD and/or to
whom the PWD is referred during the intervention.
In a previous process evaluation [32], we found infor-
mal discussions to be a very effective way of collecting
data in a timely fashion. Such discussions may only last
a few minutes but can deepen understanding of how the
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intervention is being delivered. We anticipate that infor-
mal discussions will be conducted throughout the WP4
with staff responsible for training and supervision and
those responsible for intervention delivery.
Process evaluation
Interviews will explore the acceptability and perceived
value of the intervention to PWD and their informal
carers. Topic guides are given in Additional file 5. We
will also explore the extent to which participants felt the
intervention was tailored, their views on the intensity of
the intervention and staff involved in delivering the
intervention and any suggested changes to the interven-
tion. PWD consenting to a qualitative interview will be
interviewed separately from their informal carer where
possible, but jointly if preferred by the participant. Inter-
views will take no longer than 60 min and will be audio
recorded with participants’ permission (as documented
on the initial study consent form; consent to recording
will be verbally confirmed at the time of the interview).
The clinical researcher undertaking baseline and
follow-up assessments will include some open-ended
questions to explore participants’ views on the outcome
measures. These qualitative data will be recorded in de-
tail on the case report form (CRF) and passed to the
qualitative team for analysis.
As described above, professionals will be observed dur-
ing intervention delivery (with the consent of the PWD
and informal carer) and during MDT meetings. The quali-
tative team will also observe the initial training and some
supervision sessions. The importance of observing super-
vision was highlighted in a previous study where it re-
vealed specific areas in which additional training was
required [32]. Information from the observation will in-
form subsequent interviews and informal discussions with
professionals and will allow us to follow up emerging is-
sues in more detail. Interviews with MDT members will
explore the perceived value and sustainability of the MDT
meetings as part of the intervention. Alternative models of
obtaining specialist input will also be explored.
Interviews with professionals to whom PWD and/or
informal carers have been referred as a result of the
intervention and/or who have been providing care to
participants during intervention delivery will explore
their experiences of the intervention, the ‘fit’ of the
intervention with the care they provide and suggested
changes or improvements to the content, delivery or
timing of the intervention. The appropriateness of refer-
rals will also be explored.
Withdrawal criteria
PWD and informal carers will have the right to withdraw
from intervention delivery, outcome assessment and/or
the (optional) qualitative component, without having to
give a reason, although they may give one if they wish to
do so. Investigator sites will clarify with participants which
aspects of the study they wish to withdraw from and
document this on a study withdrawal form.
The investigator may discontinue a participant from
the study at any time if necessary.
Due to the nature of the disease, some participants
may become very ill or die before completion of the
study. Participants who withdraw from the trial will not
be replaced routinely, but if an unexpectedly large num-
ber of participants withdraw early, it may be necessary
to replace them to achieve adequate data to answer our
research questions.
Professionals who are not directly involved in inter-
vention supervision or delivery will also have the right to
withdraw from the study at any time without having to
give a reason.
Adverse events
This is a non-drug intervention trial, using interventions
that might be offered as part of a routine physiotherapy
intervention. Dementia is progressive and associated
with comorbidity. Inter-current illness will be very com-
mon. We will aim to achieve a balance between ensuring
that any adverse events (AEs) which are likely to be re-
lated to the study are detected, and the recording of nu-
merous unrelated events.
Falls, injuries, deaths and hospital admissions will be
ascertained prospectively throughout the study. They
will be recorded through diaries which will be reviewed
regularly by the therapists and/or rehabilitation support
workers.
We will define an AE as an incident, injury or symp-
tom related to therapy sessions, or activities undertaken
independently. The most likely AEs are fatigue, minor
musculoskeletal symptoms or injuries such as muscle
stiffness, or sprains, or increased falls though increased
activity. Some conditions such as arthritis or angina may
be exacerbated by exercise. AEs will be monitored by
therapists and rehabilitation support workers, and re-
ported where they occur. All serious AEs should be re-
ported to the NHS Research Ethics Committee (REC).
Analysis
Analysis population
All analyses will be conducted on an intention to treat
basis, with sensitivity analyses used to investigate the im-
pact of removing individuals who did not receive the
intervention as allocated.
Quantitative analyses
The main analysis will be of feasibility outcomes. We will
report the numbers of eligible participants seen over the
recruitment period, and the resulting rates of recruitment,
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retention and data completion. Non completers will be
characterised. We will also assess performance of potential
outcome measures for a definitive trial. We will ascertain
data completeness of the instruments and any potential
bias in the completion of follow-up data to inform the
choice of instruments in a future trial. The majority of the
outcome data will be presented in simple descriptive tables
presenting percentages, means and standard deviations.
Health economic data
During the intervention development work, a Healthcare
Utilisation Questionnaire (HUQ) was developed and
piloted—the format and administration of this question-
naire was adapted in light of the responses and feedback.
The questionnaire will now be completed once by the
clinical researcher at the 12-week follow-up visit with in-
formation provided by the informal carer. The clinical re-
searcher will make notes on the CRF regarding the
perceived value and burden of including space in the par-
ticipant diary to make a note of services received as an
aide memoire for completing the HUQ at the end of the
study. These notes will be passed to the qualitative team
for analysis. The data collected will be analysed and pre-
sented as completion rates and descriptive statistics; this
will allow our results to be used for meta-analysis and sys-
tematic reviews.
The data will be analysed as completion rates and de-
scriptive statistics. We will look at the overall response
rates and the completion of each question in the data
collection tools (HUQ and EQ-5D-5L). This will help us
identify any potential issues with the data collection
tools and suggest amendments for a future definitive
trial. Descriptive statistics will be provided for each type
of healthcare resource reported and will be presented as
the mean number of visits and standard deviation.
We will also determine the feasibility of identifying
and estimating costs associated with the intervention
and resource use. Intervention costs will be based on the
data provided by the therapists on number of sessions,
travelling time, referrals and involvement of the MDT.
This will determine the ease of cost collection for a full
definitive trial.
Qualitative analyses
Field notes of observation and interview transcripts will
form the formal data for analysis. Normalisation process
theory (NPT) [33] will inform both data collection and
analysis. This theory is increasingly being used in studies
of the implementation of interventions in health care
(www.normalizationprocess.org) including published stud-
ies from current applicants [32, 34, 35]. Normalisation
process theory is valuable in highlighting whether prob-
lems with implementation reflect a lack of perceived rele-
vance of the intervention (coherence); the unwillingness
of participants to invest in the intervention (cognitive par-
ticipation); difficulties in delivering the intervention, such
as a lack of resource or shortfalls in skills and knowledge
(collective action); or a lack of feedback on the impacts of
the intervention or inability to adapt the intervention to
meet local needs (reflexive monitoring). Identifying key
barriers to implementation using NPT helps in deciding
how best to optimise an intervention and associated train-
ing and documentation prior to further implementation.
All field notes and interview transcripts will be anon-
ymised prior to analysis. Following the principles of the
constant comparative method, data analysis will proceed
alongside data collection. This will ensure that emerging
themes and issues can be explored in subsequent data
collection. The qualitative team will use data analysis
workshops to consider data from different sources (ob-
servation; interviews with different stakeholders; infor-
mal discussions) and develop a coding frame. Some data
analysis workshops will also include members of the ex-
tended team to offer different perspectives on the data.
Once a coding frame has been agreed, we will use NVivo
software to manage data analysis. The analyses will focus
on issues of feasibility and acceptability of the interven-
tion and will explore the extent to which views on the
intervention are consistent within and between stake-
holder groups.
Sample size consideration
The sample size for the intervention study was decided
by the expert consensus panel. Their decision reflected
their expertise as to how many participants would be
needed to measure feasibility outcomes, balanced with
the time for recruitment available during the available
funding envelope and the likely potential recruitment
rates estimated from our observational work in an earl-
ier stage of this research programme. It is anticipated
that ten participants per site will give us sufficient data
to answer feasibility questions including estimation of
potential recruitment rates, intervention adherence and
rates of completion of data outcome tools.
Criteria for progression to full trial
Stop/Go criteria have been developed for progression to
a definitive trial.
Definite Go (‘green light’) defined as follows:
 ≥ 60% of eligible participants consenting to feasibility
trial
 ≥ 80% participants attend ≥ 60% of sessions as
planned
 Retention of ≥ 70% of consented participants for
provision of key outcome data at 3 months
 The intervention can be delivered with fidelity, i.e.
the content, frequency, duration and quality of the
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intervention can be delivered as set out in the
intervention delivery manual
 An indication from qualitative interview and focus
group work that the intervention(s) is (are)
perceived as acceptable to both participants and
professionals
Definite Stop (‘red light’) defined as follows:
 < 40% of eligible participants consenting to feasibility
trial
 < 20% participants attend ≥ 60% of sessions as
planned in a given intervention arm
 Retention of < 50% of consented participants for
provision of key outcome data at 3 months
 It is clear from the process data from participants
and professionals that the intervention procedures
have low fidelity in terms of content, frequency,
duration and quality and that they are unfeasible to
deliver
 An indication from qualitative interview and focus
group work that the intervention(s) is (are) not
acceptable to participants and professionals
Intermediate outcomes will be defined as amber and
refinement of the intervention will be undertaken in
conjunction with our patient and public involvement
(PPI) panel. A decision as to whether to progress to a
full trial will be discussed by the Trial Oversight
Committee.
Research governance
Sponsor
The study will be sponsored by The Newcastle upon Tyne
Hospitals NHS Foundation Trust (NUTH) (reference 8489).
A formal agreement between the sponsor and each partici-
pating site, setting out the responsibilities of sponsor, chief
investigator (CI) and site, including site principal investigator
(PI), will be in place prior to site initiation. Evidence of local
approvals including NHS organisation research and develop-
ment (R&D) and Caldicott Guardian will be obtained prior
to site initiation. Responsibility for study design; collection,
management, analysis and interpretation of data; writing of
the report; and the decision to submit the report for publica-
tion remains with the research team.
Contact information for the study sponsor:
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle Joint Research Office
Regent Point
Regent Farm Road
Newcastle upon Tyne
NE3 3HD
Trust.R&D@nuth.nhs.uk
Indemnity
The sponsor has liability for clinical negligence that
harms individuals towards whom they have a duty of
care. NHS indemnity covers NHS staff and medical aca-
demic staff with honorary contracts conducting the trial
for potential liability in respect of negligent harm arising
from the conduct of the study at site.
External steering committee
A Trial Oversight Committee (TOC) with 75% inde-
pendent membership will provide overall supervision for
a trial on behalf of the Trial Sponsor and Trial Funder
and to ensure that the trial is conducted to the rigorous
standards set out in the Department of Health’s Research
Governance Framework for Health and Social Care and
the Guidelines for Good Clinical Practice (GCP).
Data management
Data collection tools and source document identifica-
tion Data will be handled, computerised and stored in ac-
cordance with the Data Protection Act 1998. The quality
and retention of study data will be the responsibility of the
CI. All study data will be retained in accordance with the
latest Directive on GCP (2005/28/EC) and local policy.
Monitoring, audit and inspection
Monitoring of study conduct and data collected will be
performed by a combination of central review and site
monitoring visits to ensure the study is conducted in ac-
cordance with GCP. Study site monitoring will be under-
taken on behalf of the study sponsor by the Newcastle
Clinical Trials Unit (NCTU), in agreement with the CI.
The main areas of focus will include consent and essen-
tial documents in study files. A monitoring plan will be
written, agreed and signed by the sponsor and monitor.
The study may be subject to inspection and audit by
NUTH under their remit as sponsor, and other regula-
tory bodies to ensure adherence to GCP. The investiga-
tor(s)/institutions will permit trial-related monitoring,
audits, REC review and regulatory inspection(s), provid-
ing direct access to source data/documents.
The trial may be subject to audit by representatives of
the sponsor or regulatory inspection. Each investigator
site will permit trial-related monitoring, audits and regu-
latory inspection including access to all essential and
source data relating to the trial.
The trial may be prematurely discontinued on the rec-
ommendation of the Trial Oversight Committee, spon-
sor or regulatory authority.
Discussion
Our systematic review showed that there is currently little
evidence to guide the management of falls in dementia.
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Nevertheless, it is an important area for research because
of the high burden of adverse outcomes for people with
dementia who fall and the costs to the health and social
care economy. Existing falls interventions may not be suit-
able for PWD. Our work with stakeholders and realist re-
view of the literature revealed that there are sufficient
ideas to develop a new intervention which may address
this dearth of evidence. The protocol for this study has
been developed after extensive stakeholder engagement
and observation of existing practices in conjunction with
consultation with an expert consensus panel.
The strength of our intervention is that it takes a new
approach to the problem which takes account of the dif-
fering needs of PWD and focuses on the goals which are
important to them. We will be taking a holistic approach
to the patient, assessing all potential needs and adapting
the intervention by tailoring and embedding of activities.
The activities will include both physical activities and
cognitive techniques such as dual task training.
As a feasibility study, we have included robust meas-
urement of feasibility parameters in our protocol which
will enable us to determine whether it is feasible to
proceed to a full randomised controlled trial. The
process evaluation is a strength because this will capture
detail about how the intervention is implemented and
received by all relevant stakeholders. This will enable us
to adapt the procedures to maximise the chances of suc-
cess in any future trial.
The research question addressed in this call was iden-
tified by the Health Technology Assessment Programme
(HTA) with patient and public involvement. We have
shared the brief and plans for this project with older
people and informal carers of PWD participating in
Voice North—an organisation to facilitate the involve-
ment of the public in research and product and service
development. Voice North exists to harness the skills
and experience of the public—currently over 1000
people are involved from across the North East. The
participants concurred with the HTA’s view that this is
an important area for research into the care of PWD.
Members of Voice North also gave input into all the pa-
tient and carer facing documents.
Conclusions
This study will provide the evidence as to whether it
is possible to implement the intervention designed by
the DIFRID study team in a UK NHS setting. If it is
possible, then we will seek to obtain funding for a
programme of research leading to a full randomised
controlled trial of the intervention. Implementation of
the intervention will potentially improve outcomes for
PWD who fall, their carers and the health and social
care economy.
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